Solifenacin Succinate/Tamsulosin Hydrochloride

琥珀酸索利那新/盐酸坦洛新

Report date: 2022/01/14 13:23:58

Base Information

Drug NameSolifenacin Succinate/Tamsulosin Hydrochloride
Drug Alias Name盐酸坦洛新/琥珀酸索利那新Solifenacin/TamsulosinTamsulosin and Solifenacin索利那新坦洛新Tamsulosin Hydrochloride/Solifenacin Succinate +[13] 
ClassificationSmall molecules
Mechanisms of ActionMuscarinic acetylcholine receptor M3 antagonistsAlpha-1a adrenergic receptor antagonists
TargetsAlpha-1a adrenergic receptorMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsDrug-Related Side Effects and Adverse ReactionsLower Urinary Tract SymptomsUrinary Bladder, Overactive +[5] 
Global Approved IndicationsLower Urinary Tract Symptoms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryNetherlands
Original Approved Date2013/10/07
Country/TerritoryCzechiaBelgiumUnited States +[15] 
CombinationsYes Tamsulosin HydrochlorideSolifenacin Succinate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma IncEurofarma Laboratorios Sa
Inactive CompaniesJeil Pharmaceutical Co LtdAstellas Pharma Europe Bv
Active IndicationsLower Urinary Tract SymptomsProstatic Hyperplasia
Inactive IndicationsDrug-Related Side Effects and Adverse ReactionsUrinary Bladder, OveractiveUrinary Bladder Neck Obstruction

Other Information

ATC CodeG04CA53
Related LinksN/A